Investing.com - Coherus BioSciences (NASDAQ: CHRS) reported second quarter EPS of $-0.140, $0.11 better than the analyst estimate of $-0.250. Revenue for the quarter came in at $65M versus the consensus estimate of $56.41M.
Guidance
Coherus BioSciences sees FY 2024 revenue of $250.000M-$265.000M versus the analyst consensus of $259.300M.
Coherus BioSciences's stock price closed at $1.29. It is down -32.110% in the last 3 months and down -71.900% in the last 12 months.
Coherus BioSciences saw 0 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Coherus BioSciences's stock price’s past reactions to earnings here.
According to InvestingPro, Coherus BioSciences's Financial Health score is "fair performance".
Check out Coherus BioSciences's recent earnings performance, and Coherus BioSciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar